FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer-Reference-Cited by-同舟云学术

FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer

Published:2016 Issue:31 Volume:22 Page:6987
ISSN:1007-9327
Container-title:World Journal of Gastroenterology
language:en
Short-container-title:WJG

Author:

Caparello Chiara,Meijer Laura L,Garajova Ingrid,Falcone Alfredo,Le Large Tessa Y,Funel Niccola,Kazemier Geert,Peters Godefridus J,Vasile Enrico,Giovannetti Elisa

Publisher

Baishideng Publishing Group Inc.

Subject

Gastroenterology,General Medicine

Reference148 articles.

1. T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma

2. A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

3. Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation

4. Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of l-leucovorin uptake and metabolism in the modulation of 5-fluorouracil efficacy and antifolate toxicity;Frontiers in Pharmacology;2024-08-21

2. Extracellular Vesicular miRNA in Pancreatic Cancer: From Lab to Therapy;Cancers;2024-06-08

3. Prolactin receptor potentiates chemotherapy through miRNAs‐induced G6PD/TKT inhibition in pancreatic cancer;The FASEB Journal;2024-05-28

4. The trend toward more target therapy in pancreatic ductal adenocarcinoma;Expert Review of Anticancer Therapy;2024-05-23

5. Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer;Current Issues in Molecular Biology;2024-03-23